|23rd October 2020||Gregory Bailey||10,191||Open or private sale||$78.89||$803,918.05|
|23rd October 2020||Gregory Bailey||212||Open or private sale||$79.94||$16,948.00|
|22nd October 2020||Gregory Bailey||21,466||Open or private sale||$79.41||$1,704,720.24|
|22nd October 2020||Gregory Bailey||3,100||Open or private sale||$79.88||$247,632.03|
|19th October 2020||Gregory Bailey||4,554||Open or private sale||$78.98||$359,655.34|
|16th October 2020||Gregory Bailey||3,748||Open or private sale||$78.88||$295,638.12|
|12th October 2020||Gregory Bailey||6,729||Open or private sale||$78.87||$530,740.45|
|8th October 2020||Kimberly Gentile||15,781||Open or private sale||$76.42||$1,205,938.26|
|8th October 2020||Kimberly Gentile||5,261||Open or private sale||$75.62||$397,843.66|
|8th October 2020||Kimberly Gentile||23,500||Exercise of derivative||$9.29||$218,315.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.
Biohaven Pharmaceutical Holding Co. Ltd. engages in the research and development of late-stage product candidates targeting neurological diseases. It focuses on a pipeline of product candidates that represent mechanistic platforms. The company was founded in 2013 and is headquartered in New Haven, CT.